Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin

A Randomized, Double-blind, Two-arm, Parallel-group, Single Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Two Formulations of Trastuzumab (CT-P6 and US-licensed Herceptin) in Healthy Subjects

This is a double-blind, two-arm, parallel-group, single-dose study.

This is a double-blind, two-arm, parallel-group, single-dose study. A total of 70 healthy male subjects will be enrolled.

Inclusion Criteria:

1. Healthy male subject
2. Subject voluntarily agrees to participate in this study

Exclusion Criteria:

1. Female.
2. Subject has a medical condition of disease including one or more.
3. Smoker